Overview of the Fundraising Milestone
Belgian venture capital firm HERAN Partners has closed a major €90 million fundraising round. The fund, known as HERAN HealthTech Fund II, marks a significant step forward for European healthtech investment. Moreover, the firm plans to grow the total fund size to between €110 million and €120 million in the near future.
HERAN Partners focuses on early-stage medtech and healthtech companies across Europe. Their mission is clear: make healthcare and life sciences research more efficient, data-driven, and scalable. As a result, Fund II positions itself at the heart of a rapidly evolving sector.
Key Investors Behind HERAN Fund II
European Investment Fund Leads the Charge
The European Investment Fund (EIF) made a €20 million commitment to Fund II. This contribution signals strong institutional confidence in HERAN’s strategy and the broader European healthtech ecosystem.
Flemish Investor PMV Steps Up
Flemish investment company PMV also increased its participation compared to the first fund. PMV now commits €10 million, reflecting its growing trust in HERAN’s ability to deliver results.
Additional Institutional Backers
Several other investors joined the fund as well. These include BNP Paribas Fortis, Finance & Invest Brussels, and KU Leuven Research & Development. Furthermore, entrepreneurs and management teams from HERAN’s first fund also returned as backers. Their continued support speaks to the firm’s strong track record and investor relations.
Building on a Strong First Fund
First Fund Delivered Successful Exits
HERAN’s first fund closed at €75.5 million and delivered multiple successful exits. Therefore, Fund II launches with a solid foundation and proven momentum behind it.
An Expanded Team
The team has grown with new partner appointments. These additions bring fresh expertise and broader networks to strengthen the fund’s operational capacity. Consequently, HERAN enters Fund II better equipped than ever before.
Investment Focus and Strategy
Targeting Seed and Series A Companies
Fund II will back seed and Series A companies. These are early-stage startups developing enabling technologies across software, hardware, and services. Each company must address real-world healthcare needs with scalable, practical solutions.
A Data-Driven Approach to Healthcare
HERAN specifically targets companies that make healthcare delivery more efficient and research more data-driven. In addition, they support innovations that reduce friction in life sciences research and development pipelines. This targeted approach helps differentiate Fund II from generalist venture capital funds.
Cross-Border European Coverage
HERAN operates across Europe, giving portfolio companies access to a wide network of partners, hospitals, and research institutions. Thus, early-stage companies gain not just capital but also strategic support across borders.
First Portfolio Investment: Pharmacelera
A Strong Opening Move
Fund II has already made its first investment in Pharmacelera, a Spain-based company. Pharmacelera uses advanced computing methods to accelerate drug discovery. This investment reflects HERAN’s commitment to supporting deep-tech healthcare innovation at the frontier of computational biology.
Why Pharmacelera Stands Out
Drug discovery is one of the most time-intensive and costly processes in medicine. Pharmacelera’s technology directly tackles this challenge. As a result, it aligns perfectly with HERAN’s mission to make life sciences research faster, smarter, and more scalable.
What This Means for European Healthtech
The successful close of HERAN HealthTech Fund II sends a positive signal to the broader European healthtech ecosystem. First, it confirms that institutional investors are actively backing early-stage medical innovation across the continent. Second, it demonstrates that Belgian venture capital is playing a leading role in shaping the future of healthcare technology.
Additionally, the fund’s expansion toward €110 million to €120 million suggests continued momentum. More capital flowing into seed and Series A healthtech companies means faster innovation cycles and better outcomes for patients and healthcare systems alike.
European healthtech is growing, and HERAN Partners is helping to lead that charge.
